Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit
Rapport Therapeutics (Nasdaq: RAPP), a clinical-stage biotech company developing small molecule medicines for CNS disorders, has announced its participation in two upcoming investor conferences. The company will present at:
1. The Morgan Stanley 22nd Annual Global Healthcare Conference in New York City on September 5, 2024, at 4:50 pm ET.
2. TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit (Virtual) on September 26, 2024, at 11:40 am ET.
A live and archived webcast of the Morgan Stanley Conference fireside chat will be available on the company's investor relations website. This presentation offers investors an opportunity to gain insights into Rapport Therapeutics' progress in developing innovative treatments for central nervous system disorders.
Rapport Therapeutics (Nasdaq: RAPP), una società biotech in fase clinica che sviluppa farmaci a piccole molecole per i disturbi del sistema nervoso centrale, ha annunciato la sua partecipazione a due importanti conferenze per investitori. L'azienda presenterà:
1. Il 22° Annual Global Healthcare Conference di Morgan Stanley a New York il 5 settembre 2024, alle 16:50 ET.
2. Il 4° Annual Novel Mechanisms in Neuropsychiatry Summit di TD Cowen (Virtuale) il 26 settembre 2024, alle 11:40 ET.
Un webcast in diretta e registrato della chat al Morgan Stanley Conference sarà disponibile sul sito web delle relazioni con gli investitori dell'azienda. Questa presentazione offre agli investitori l'opportunità di acquisire informazioni sui progressi di Rapport Therapeutics nello sviluppo di trattamenti innovativi per i disturbi del sistema nervoso centrale.
Rapport Therapeutics (Nasdaq: RAPP), una empresa biotecnológica en etapa clínica que desarrolla medicamentos de pequeñas moléculas para trastornos del sistema nervioso central, ha anunciado su participación en dos conferencias de inversores próximas. La empresa presentará en:
1. La 22.ª Conferencia Anual Global de Atención Médica de Morgan Stanley en Nueva York el 5 de septiembre de 2024, a las 4:50 p. m. ET.
2. La 4.ª Cumbre Anual de Nuevos Mecanismos en Neuropsiquiatría de TD Cowen (Virtual) el 26 de septiembre de 2024, a las 11:40 a. m. ET.
Una transmisión en vivo y grabada de la conversación en la conferencia de Morgan Stanley estará disponible en el sitio web de relaciones con los inversores de la empresa. Esta presentación ofrece a los inversores la oportunidad de obtener información sobre el progreso de Rapport Therapeutics en el desarrollo de tratamientos innovadores para trastornos del sistema nervioso central.
Rapport Therapeutics (Nasdaq: RAPP), 중추신경계 장애를 위한 소분자 의약품을 개발하는 임상 단계의 생명공학 회사가 두 개의 예정된 투자자 회의에 참여한다고 발표했습니다. 회사는 다음에서 발표할 예정입니다:
1. 모건 스탠리 제22회 글로벌 헬스케어 컨퍼런스가 2024년 9월 5일 뉴욕에서 오후 4시 50분 ET에 열립니다.
2. TD Cowen 제4회 신경정신의학의 새로운 메커니즘 서밋 (온라인) 2024년 9월 26일 오전 11시 40분 ET에 진행됩니다.
모건 스탠리 회의 화상 대화의 라이브 및 아카이브 웹캐스트는 회사의 투자자 관계 웹사이트에서 제공될 예정입니다. 이 발표는 투자자들에게 Rapport Therapeutics가 중추신경계 장애를 위한 혁신적인 치료법 개발에 대한 통찰력을 얻을 수 있는 기회를 제공합니다.
Rapport Therapeutics (Nasdaq: RAPP), une société biopharmaceutique en phase clinique développant des médicaments à petites molécules pour les troubles du système nerveux central, a annoncé sa participation à deux prochaines conférences pour investisseurs. L'entreprise présentera lors :
1. De la 22e Conférence Annuelle Mondiale sur les Soins de Santé de Morgan Stanley à New York le 5 septembre 2024, à 16h50 ET.
2. Du 4e Sommet Annuel sur les Nouveaux Mécanismes en Neuropsychiatrie de TD Cowen (virtuel) le 26 septembre 2024, à 11h40 ET.
Un webinaire en direct et enregistré de la conversation d'évaluation au Morgan Stanley Conference sera disponible sur le site Web des relations avec les investisseurs de l'entreprise. Cette présentation offre aux investisseurs la possibilité d'obtenir des informations sur les avancées de Rapport Therapeutics dans le développement de traitements innovants pour les troubles du système nerveux central.
Rapport Therapeutics (Nasdaq: RAPP), ein biopharmazeutisches Unternehmen in der klinischen Phase, das kleine Molekülmedikamente für Störungen des zentralen Nervensystems entwickelt, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. Das Unternehmen wird auf folgenden Veranstaltungen präsentieren:
1. Auf der 22. Jahrestagung der Global Healthcare Conference von Morgan Stanley in New York City am 5. September 2024 um 16:50 Uhr ET.
2. Auf dem 4. jährlichen Gipfel über neue Mechanismen in der Neuropsychiatrie von TD Cowen (virtuell) am 26. September 2024 um 11:40 Uhr ET.
Ein Live- und aufgezeichnetes Webcast des Morgan Stanley Conference Fireside Chats wird auf der Investor Relations-Website des Unternehmens verfügbar sein. Diese Präsentation bietet Anlegern die Möglichkeit, Einblicke in die Fortschritte von Rapport Therapeutics bei der Entwicklung innovativer Behandlungen für Störungen des zentralen Nervensystems zu gewinnen.
- None.
- None.
BOSTON and SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders, today announced that management will present at two upcoming investor conferences:
- The Morgan Stanley 22nd Annual Global Healthcare Conference in New York City on Thursday, September 5, 2024, at 4:50 pm ET.
- TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit (Virtual) on Thursday, September 26, 2024, at 11:40 am ET.
Interested parties may access a live and archived webcast of the Morgan Stanley Conference fireside chat on the “Investors” section of the company’s website at: https://investors.rapportrx.com.
About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformational precision neuromedicines for patients suffering from central nervous system (CNS) disorders. The Company’s founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport’s RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead clinical program, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently advancing RAP-219 in clinical trials in focal epilepsy, peripheral neuropathic pain, and bipolar disorder. Additional preclinical and late-stage discovery stage programs are also underway, targeting CNS disorders including chronic pain and hearing disorders.
Contact
Julie DiCarlo
Head of Communications & IR
Rapport Therapeutics
jdicarlo@rapportrx.com
Source: https://www.rapportrx.com/
FAQ
When is Rapport Therapeutics (RAPP) presenting at the Morgan Stanley Global Healthcare Conference?
What is the date and time of Rapport Therapeutics' (RAPP) presentation at TD Cowen's Neuropsychiatry Summit?
How can investors access Rapport Therapeutics' (RAPP) presentation at the Morgan Stanley Conference?
What type of medicines is Rapport Therapeutics (RAPP) developing?
